Brainstorm Cell Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

• Brainstorm Cell Therapeutics Inc BCLI.OQ reported a quarterly adjusted loss of 51 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -45 cents. The mean expectation of two analysts for the quarter was for a loss of 57 cents per share. Wall Street expected results to range from -70 cents to -45 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Brainstorm Cell Therapeutics Inc's reported EPS for the quarter was a loss of 51 cents​.

• The company reported a quarterly loss of $2.71 million.

• Brainstorm Cell Therapeutics Inc shares had fallen by 67.3% this quarter and lost 72.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 9.5% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Brainstorm Cell Therapeutics Inc is $22.51

This summary was machine generated from LSEG data November 15 at 02:10 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)